HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Health (OTC Drugs)

Set Alert for Health (OTC Drugs)

Regulation/Legislation Explore this Topic

Set Alert for Regulation and Legislation {Health}

Latest From Regulation, Legislation & Health

US COVID-19 Fraud: After Facebook Posts, Regulators Don’t ‘Friend’ ChromaDex

ChromaDex is among latest targets of FDA/FTC joint warnings identifying claims on websites as well as in social media posts that render products unapproved and misbranded drugs indicated to prevent or treat COVID-19.

FDA Dietary Supplements

US FDA Details Trials To Evaluate New Drugs' Potential Interactions With Heartburn Remedies

Draft guidance on testing investigational drugs for drug-drug interactions with ingredients used in antacids, histamine H2-receptor antagonists and proton pump inhibitors points to including labels warnings on the new drugs about their concomitant use with the heartburn remedies.

OTC Drugs Guidance Documents

E-cigarette NRT Outlook Heated By Combining With Counseling, Nicotine-Tapering Strategy

Results of three-year study conducted at 17 Canadian sites suggest that e-cigarettes use combined with counseling significantly increased abstinence from smoking cigarettes compared to receiving counseling alone.

OTC Drugs Research & Development

CBD Health Benefits More Attractive To Women? FDA Prioritizes Research Into Utero Effects

Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA  neuroscientist Andrew Shen.

Cannabidiol CBD International

US COVID-19 Fraud: Latest Chloride Dioxide Products Linked To Claims Are Oral Rinses

Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.

OTC Drugs Coronavirus COVID-19

Loud And Clear Need In US For OTC Hearing Aids For Mild To Moderate Loss, Congress Tells FDA

Hearing loss is one of the most common conditions affecting older US consumers, with nearly one in three between the ages of 65 and 74 having difficulty hearing, Sens. Warren and Grassley and Resp. Kennedy and Carter note in urging FDA to finalize regulations allowing certain hearing aids to be sold OTC.

OTC Devices Policy
See All

Business Explore this Topic

Set Alert for Business {Health}

Latest From Deals & Health

Church & Dwight Takes Homeopathic Turn For OTC Sales Driver, Acquires Zicam Marketer Matrixx

C&D CEO Matthew Farrell says Zicam has 73% share in the US zinc-containing wellness product market. It's acquiring marketer Matrixx Initiatives at a price almost 15 times Zicam brand’s projected 2021 EBITDA.

M & A OTC Drugs

Dr Reddy's Strengthens Russian OTC Portfolio Through Glenmark Deal

Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.

Deals OTC Devices

Jefferies' Survey Predicts M&A Rebound In 2021

An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies. 

International Health
See All

Latest From Business Strategies & Health

Arcadia Stubs Toe In Nail Fungus Ad Challenge, Giving Advantice Foot In Door On Appeal

Arcadia prohibited from arguing against Advantice’s appeal of National Advertising Division decision that Kerasal Fungal Nail Renewal ad claims weren’t supported. Arcadia violated confidentiality rule by publicizing NAD decision before the review was officially closed.

OTC Drugs Ad Complaints

Church & Dwight Takes Homeopathic Turn For OTC Sales Driver, Acquires Zicam Marketer Matrixx

C&D CEO Matthew Farrell says Zicam has 73% share in the US zinc-containing wellness product market. It's acquiring marketer Matrixx Initiatives at a price almost 15 times Zicam brand’s projected 2021 EBITDA.

M & A OTC Drugs

Dr Reddy's Strengthens Russian OTC Portfolio Through Glenmark Deal

Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.

Deals OTC Devices
See All

Latest From Sales & Earnings & Health

Edgewell Finds COVID Bright Side: Wet Ones On Way To Becoming ‘Little Mega-Brand’

Skin hygiene is one of several categories where Edgewell Personal Care has a “right to win" after 18 months of renovations, according to the company’s 20 November Investor Day presentation. The firm has doubled its production capacity and has plans for a “full suite” of product innovation to build on Wet Ones’ 60% growth in fiscal 2020.

Business Strategies Sales & Earnings

Balancing Beauty Lineup With International And Regional Brands Factors In J&J Consumer Growth

While J&J benefits from “underlying strength” of its large skin care brands, it targets “regular additions of local, smaller brands,’ says global consumer business head Thibaut Mongon. Portfolio balance of international and localized brands helps it weather economic uncertainty during the COVID-19 pandemic.

Business Strategies Cosmetics

Prestige Consumer Expects 4% Sales Dip For Its FY2021 As COVID-19 Clouds Economic Forecast

North American sales for the consumer health segment in the quarter reached $216.6m core products on women’s health, analgesics, oral care and ear and eye care categories, partially offset by declines in cough and cold products as well as gastrointestinal products.

Sales & Earnings OTC Drugs
See All

Latest From Legal Issues & Health

NAD Issues Latest Decision In Fungal Nail Brands’ Claims Feud

Three years ago, the Kerasal fungal nail brand brought a challenge to the National Advertising Division that decimated claims for competing Fungi-Nail products and got federal agencies involved. The shoe is now on the other foot, as the NAD agrees with Fungi-Nail that a slew of Kerasal claims should be discontinued.

United States Advertising, Marketing & Sales

With Irish Tax Assessment Upheld, Perrigo Plumbs US-Ireland Pact To Lower Debt

With both Ireland and US imposing tax assessments on same revenues – sales by Elan – tax agency officials from the countries will, at the request of Perrigo, negotiate whether both or one will demand payment and whether the amount will be lowered.

Tax OTC Drugs

Court Ruling On Perrigo Appeal Of Nearly $2Bn Irish Tax Debt From Elan Deal Due With Q3 Results

Perrigo says on 4 November, Irish High Court will publish decision from a trial on the firm’s challenge to Irish Office of the Revenue Commissioners’ order to pay additional taxes from its acquisition of Elan. Perrigo moved its Q3 earnings briefing scheduled for 8 a.m. EDT the same day to 4:30 p.m.

Tax OTC Drugs
See All

Marketing Explore this Topic

Set Alert for Marketing {Health}

Latest From Launches & Health

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Japan Europe

J&J Leverages Power Of Digital Personalization With Nicorette UK Extension

Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.

United Kingdom Health

Health And Wellness Trademark Review 24 November, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Trademarks OTC Drugs
See All

Latest From Ad Campaigns & Health

New Date For The OTC Marketing Awards 2021

The OTC Marketing Awards – the biggest night of the year for the British consumer healthcare industry – will now take place in Summer 2021 after careful consideration. There is also a new entry deadline.

OTC Drugs Innovation

Stada UK Partners With Diabetes Charity To Promote Foot Health

Diabetes-related foot amputations are on the rise in the UK. Stada through its UK subsidiary Thornton & Ross is partnering with Diabetes UK to promote foot health and the benefits of using its leading OTC foot-care brand, Flexitol. 

Health OTC Drugs

‘Swipe Right’ For Rennie – Bayer Partners With Tinder For UK Marketing Campaign

Bayer Consumer Care matches Rennie with popular dating app Tinder in the UK for an innovative new digital marketing campaign, which uses "branded profile cards" to drive engagement with the firm's flagship heartburn brand. 

Health OTC Drugs
See All

Latest From Ad Complaints & Health

Arcadia Stubs Toe In Nail Fungus Ad Challenge, Giving Advantice Foot In Door On Appeal

Arcadia prohibited from arguing against Advantice’s appeal of National Advertising Division decision that Kerasal Fungal Nail Renewal ad claims weren’t supported. Arcadia violated confidentiality rule by publicizing NAD decision before the review was officially closed.

OTC Drugs Ad Complaints

US COVID-19 Fraud: After Facebook Posts, Regulators Don’t ‘Friend’ ChromaDex

ChromaDex is among latest targets of FDA/FTC joint warnings identifying claims on websites as well as in social media posts that render products unapproved and misbranded drugs indicated to prevent or treat COVID-19.

FDA Dietary Supplements

NAD Issues Latest Decision In Fungal Nail Brands’ Claims Feud

Three years ago, the Kerasal fungal nail brand brought a challenge to the National Advertising Division that decimated claims for competing Fungi-Nail products and got federal agencies involved. The shoe is now on the other foot, as the NAD agrees with Fungi-Nail that a slew of Kerasal claims should be discontinued.

United States Advertising, Marketing & Sales
See All
UsernamePublicRestriction

Register